BioXcel Therapeutics Expands Leadership Team with Mark Pavao as Acting Chief Commercial Officer
BioXcel Therapeutics (Nasdaq:
BTAI) appointed Mark Pavao as Acting Chief Commercial Officer on January 12, 2026, to lead launch planning for IGALMI in the at-home setting.1235
Mark Pavao brings over 30 years of experience in CNS commercial leadership, including pre-launch planning and commercialization of therapies like Abilify.1
The company plans to submit a supplemental New Drug Application (sNDA) in January 2026 for FDA approval of IGALMI for at-home treatment of acute agitation in bipolar disorders and schizophrenia.13
Potential launch of IGALMI for at-home use is targeted as early as year-end 2026, pending FDA approval, addressing an unmet need with no existing FDA-approved at-home treatments.1
CEO Vimal Mehta emphasized the strategic importance of Pavao's expertise for commercializing IGALMI and maximizing its value.1
Sources:
1. https://www.stocktitan.net/news/BTAI/bio-xcel-therapeutics-expands-leadership-team-to-prepare-for-launch-0hg5ugpea2si.html
2. https://www.tradingview.com/news/tradingview:5637bce24858d:0-bioxcel-therapeutics-announces-interim-chief-commercial-officer/
3. https://www.tipranks.com/news/company-announcements/bioxcel-therapeutics-names-interim-cco-amid-igalmi-expansion